These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 26923585)

  • 1. Identification of a Post-translational Modification with Ribitol-Phosphate and Its Defect in Muscular Dystrophy.
    Kanagawa M; Kobayashi K; Tajiri M; Manya H; Kuga A; Yamaguchi Y; Akasaka-Manya K; Furukawa JI; Mizuno M; Kawakami H; Shinohara Y; Wada Y; Endo T; Toda T
    Cell Rep; 2016 Mar; 14(9):2209-2223. PubMed ID: 26923585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Muscular Dystrophy with Ribitol-Phosphate Deficiency: A Novel Post-Translational Mechanism in Dystroglycanopathy.
    Kanagawa M; Toda T
    J Neuromuscul Dis; 2017; 4(4):259-267. PubMed ID: 29081423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDP-glycerol inhibits the synthesis of the functional
    Imae R; Manya H; Tsumoto H; Osumi K; Tanaka T; Mizuno M; Kanagawa M; Kobayashi K; Toda T; Endo T
    J Biol Chem; 2018 Aug; 293(31):12186-12198. PubMed ID: 29884773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ISPD Overexpression Enhances Ribitol-Induced Glycosylation of α-Dystroglycan in Dystrophic FKRP Mutant Mice.
    Cataldi MP; Blaeser A; Lu P; Leroy V; Lu QL
    Mol Ther Methods Clin Dev; 2020 Jun; 17():271-280. PubMed ID: 31988979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ISPD produces CDP-ribitol used by FKTN and FKRP to transfer ribitol phosphate onto α-dystroglycan.
    Gerin I; Ury B; Breloy I; Bouchet-Seraphin C; Bolsée J; Halbout M; Graff J; Vertommen D; Muccioli GG; Seta N; Cuisset JM; Dabaj I; Quijano-Roy S; Grahn A; Van Schaftingen E; Bommer GT
    Nat Commun; 2016 May; 7():11534. PubMed ID: 27194101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycosylation with ribitol-phosphate in mammals: New insights into the O-mannosyl glycan.
    Manya H; Endo T
    Biochim Biophys Acta Gen Subj; 2017 Oct; 1861(10):2462-2472. PubMed ID: 28711406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Muscular Dystrophy Gene TMEM5 Encodes a Ribitol β1,4-Xylosyltransferase Required for the Functional Glycosylation of Dystroglycan.
    Manya H; Yamaguchi Y; Kanagawa M; Kobayashi K; Tajiri M; Akasaka-Manya K; Kawakami H; Mizuno M; Wada Y; Toda T; Endo T
    J Biol Chem; 2016 Nov; 291(47):24618-24627. PubMed ID: 27733679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ribitol restores functionally glycosylated α-dystroglycan and improves muscle function in dystrophic FKRP-mutant mice.
    Cataldi MP; Lu P; Blaeser A; Lu QL
    Nat Commun; 2018 Aug; 9(1):3448. PubMed ID: 30150693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytidine Diphosphate-Ribitol Analysis for Diagnostics and Treatment Monitoring of Cytidine Diphosphate-l-Ribitol Pyrophosphorylase A Muscular Dystrophy.
    van Tol W; van Scherpenzeel M; Alsady M; Riemersma M; Hermans E; Kragt E; Tasca G; Kamsteeg EJ; Pennings M; van Beusekom E; Vermeulen JR; van Bokhoven H; Voermans NC; Willemsen MA; Ashikov A; Lefeber DJ
    Clin Chem; 2019 Oct; 65(10):1295-1306. PubMed ID: 31375477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structures of fukutin-related protein (FKRP), a ribitol-phosphate transferase related to muscular dystrophy.
    Kuwabara N; Imae R; Manya H; Tanaka T; Mizuno M; Tsumoto H; Kanagawa M; Kobayashi K; Toda T; Senda T; Endo T; Kato R
    Nat Commun; 2020 Jan; 11(1):303. PubMed ID: 31949166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDP-ribitol prodrug treatment ameliorates ISPD-deficient muscular dystrophy mouse model.
    Tokuoka H; Imae R; Nakashima H; Manya H; Masuda C; Hoshino S; Kobayashi K; Lefeber DJ; Matsumoto R; Okada T; Endo T; Kanagawa M; Toda T
    Nat Commun; 2022 Apr; 13(1):1847. PubMed ID: 35422047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribitol-phosphate-a newly identified posttranslational glycosylation unit in mammals: structure, modification enzymes and relationship to human diseases.
    Kanagawa M; Toda T
    J Biochem; 2018 May; 163(5):359-369. PubMed ID: 29394359
    [No Abstract]   [Full Text] [Related]  

  • 13. Cell endogenous activities of fukutin and FKRP coexist with the ribitol xylosyltransferase, TMEM5.
    Nishihara R; Kobayashi K; Imae R; Tsumoto H; Manya H; Mizuno M; Kanagawa M; Endo T; Toda T
    Biochem Biophys Res Commun; 2018 Mar; 497(4):1025-1030. PubMed ID: 29477842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCYT2 synthesizes CDP-glycerol in mammals and reduced PCYT2 enhances the expression of functionally glycosylated α-dystroglycan.
    Imae R; Manya H; Tsumoto H; Miura Y; Endo T
    J Biochem; 2021 Oct; 170(2):183-194. PubMed ID: 34255834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NAD+ enhances ribitol and ribose rescue of α-dystroglycan functional glycosylation in human FKRP-mutant myotubes.
    Ortiz-Cordero C; Magli A; Dhoke NR; Kuebler T; Selvaraj S; Oliveira NA; Zhou H; Sham YY; Bang AG; Perlingeiro RC
    Elife; 2021 Jan; 10():. PubMed ID: 33513091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemical and Chemo-Enzymatic Syntheses of Glycans Containing Ribitol Phosphate Scaffolding of Matriglycan.
    Tamura JI; Tamura T; Hoshino S; Imae R; Kato R; Yokono M; Nagase M; Ohno S; Manabe N; Yamaguchi Y; Manya H; Endo T
    ACS Chem Biol; 2022 Jun; 17(6):1513-1523. PubMed ID: 35670527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired viability of muscle precursor cells in muscular dystrophy with glycosylation defects and amelioration of its severe phenotype by limited gene expression.
    Kanagawa M; Yu CC; Ito C; Fukada S; Hozoji-Inada M; Chiyo T; Kuga A; Matsuo M; Sato K; Yamaguchi M; Ito T; Ohtsuka Y; Katanosaka Y; Miyagoe-Suzuki Y; Naruse K; Kobayashi K; Okada T; Takeda S; Toda T
    Hum Mol Genet; 2013 Aug; 22(15):3003-15. PubMed ID: 23562821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of post-phosphoryl modification in dystroglycanopathy mouse models and wild-type tissues expressing non-laminin binding form of α-dystroglycan.
    Kuga A; Kanagawa M; Sudo A; Chan YM; Tajiri M; Manya H; Kikkawa Y; Nomizu M; Kobayashi K; Endo T; Lu QL; Wada Y; Toda T
    J Biol Chem; 2012 Mar; 287(12):9560-7. PubMed ID: 22270369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AAV-mediated transfer of FKRP shows therapeutic efficacy in a murine model but requires control of gene expression.
    Gicquel E; Maizonnier N; Foltz SJ; Martin WJ; Bourg N; Svinartchouk F; Charton K; Beedle AM; Richard I
    Hum Mol Genet; 2017 May; 26(10):1952-1965. PubMed ID: 28334834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human ISPD Is a Cytidyltransferase Required for Dystroglycan O-Mannosylation.
    Riemersma M; Froese DS; van Tol W; Engelke UF; Kopec J; van Scherpenzeel M; Ashikov A; Krojer T; von Delft F; Tessari M; Buczkowska A; Swiezewska E; Jae LT; Brummelkamp TR; Manya H; Endo T; van Bokhoven H; Yue WW; Lefeber DJ
    Chem Biol; 2015 Dec; 22(12):1643-52. PubMed ID: 26687144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.